Clinical Trials Logo

Hepatic Complication clinical trials

View clinical trials related to Hepatic Complication.

Filter by:
  • None
  • Page 1

NCT ID: NCT03923816 Not yet recruiting - Clinical trials for Hepatic Complication

Implication of Fluid Strategies Upon Hepatic Outcome in Hepatobiliary Surgery

Start date: October 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

compare the effect of two different protocol of fluid therapy in patients undergoing elective hepatobiliary surgery under general anesthesia regarding hemodynamics and SGPT change pre- and postoperative.

NCT ID: NCT02925689 Active, not recruiting - Renal Failure Clinical Trials

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01907802 Terminated - Renal Failure Clinical Trials

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Start date: August 23, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01888302 Completed - Clinical trials for Hepatic Complication

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

Start date: September 2013
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sirolimus with gemcitabine hydrochloride and cisplatin may prevent disease recurrence in patients with a high risk of recurrence after a liver transplant or surgery.